MBX Biosciences Appoints Soued as CCO with 160,000-Option Grant; Q2 Webinar Scheduled
MBX•MBX Biosciences appointed Mark R. Soued as Chief Commercial Officer and granted him 160,000 stock options at a $29.78 exercise price, vesting over four years. Microbix Biosystems will release its Q2 fiscal 2026 results before trading on May 14 and host a 10:00 AM ET webinar.
1. Appointment of Chief Commercial Officer
MBX Biosciences appointed Mark R. Soued, MBA, as Chief Commercial Officer. Soued joins with over two decades of leadership at Alnylam and Pfizer and will lead commercialization of precision peptide therapies for endocrine and metabolic disorders.
2. Inducement Equity Award Details
On May 1, 2026, the board approved a non-qualified stock option award for 160,000 shares at a $29.78 exercise price, matching the closing stock price on that date. The options will vest 25% on April 29, 2027, with the remainder vesting monthly over the next three years, subject to Soued’s continued service.
3. Q2 Fiscal 2026 Results Schedule
Microbix Biosystems expects to file its Q2 fiscal 2026 financial statements, MD&A and results news release before trading on May 14, 2026. At 10:00 AM ET, Microbix will host a webinar featuring its CEO, CFO and COO to discuss the results.
